The University of Bristol and spin-out firm Imophoron are set to assess Covid-19 vaccine candidates in-vivo in a pre-clinical programme.
Imophoron has generated several candidates based on its ADDomer vaccine platform, a synthetic, self-assembling, virus-like particle (VLP).
The company collaborated with the University of Bristol’s Covid-19 Emergency Research (UNCOVER) Group and will lead the vaccine development.
Preclinical tests are expected to begin within weeks. Imophoron founder and CEO Frederic Garzoni said: “We have optimised our process and can now design and roll-out potential vaccines in about two weeks, ready for testing. “With our technology, we hope to contribute to resolving the major health and economic threats caused by